close

Clinical Trials

Date: 2017-06-28

Type of information: Treatment of the first patient

phase: 1-2

Announcement: treatment of the first patient

Company: CytomX Therapeutics (USA - CA)

Product: CX-2009

Action mechanism:

  • probody/antibody drug conjugate. CX-2009 is a probody drug conjugate (PDC) that targets cell surface protein CD-166. CD-166 is highly and homogeneously expressed on multiple tumor types, such as breast cancer, endometrial cancer and prostate cancer. CytomX has demonstrated that CD-166 effectively internalizes antibody-drug conjugates resulting in potent cell killing in-vitro. CX-2009 is designed to target CD-166 specifically in the tumor microenvironment and deliver the tubulin-destabilizing maytansine payload, DM4, to cancer cells.
  • In 2014, CytomX entered into a license agreement with ImmunoGen, Inc. to develop PDCs against a defined number of targets, bringing together CytomX's proprietary antibody masking technology and tumor-selective protease substrates with ImmunoGen's highly potent antibody drug conjugate cell-killing agents and engineered linkers. CX-2009 is wholly owned by CytomX.

Disease: advanced solid tumors including non-small cell lung cancer, breast cancer, ovarian cancer, endometrial cancer, cholangiocarcinoma (bile duct cancer), head and neck cancer and castration-resistant prostate cancer

Therapeutic area: Cancer - Oncology

Country: USA

Trial details: PROCLAIM-CX-2009 is a dose-finding Phase 1/2 study evaluating CX-2009 as monotherapy in patients with select cancer types, including non-small cell lung cancer, breast cancer, ovarian cancer, endometrial cancer, cholangiocarcinoma (bile duct cancer), head and neck cancer and castration-resistant prostate cancer. The objectives of the study are to establish the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of CX-2009.(NCT03149549)

Latest news:

  • • On June 28, 2017, CytomX Therapeutics announced the treatment of the first patient in the PROCLAIM-CX-2009 study (Probody Clinical Assessment In Man), a Phase 1/2 clinical trial evaluating CX-2009 as monotherapy in patients with select advanced solid tumors. CX-2009 is the first Probody drug conjugate (PDC) to enter the clinic.
  • CX-2009 is being studied within PROCLAIM, CytomX’s international modular umbrella clinical trial program that encompasses the Phase 1/2 development of multiple Probody therapeutics.

Is general: Yes